Spyre Therapeutics, Inc. (SYRE) stock
SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
$101.46+7.65 (+8.15%)
Close on Nov 18, 2026Market cap $8.95BP/E –Yield –
Spyre Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Spyre Therapeutics's total assets was $1.17B at Jun 30, 2026. For fiscal 2025 it was $777.78M, up 27.8% from the year before. Over ten years it grew 35.0% a year on average. The highest annual figure on record is $777.78M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $777.78M | +27.8% |
| FY2024 | Dec 31, 2024 | $608.48M | +78.0% |
| FY2023 | Dec 31, 2023 | $341.86M | +380.5% |
| FY2022 | Dec 31, 2022 | $71.14M | -35.3% |
| FY2021 | Dec 31, 2021 | $109.93M | -32.0% |
| FY2020 | Dec 31, 2020 | $161.62M | +94.3% |
| FY2019 | Dec 31, 2019 | $83.18M | +7.0% |
| FY2018 | Dec 31, 2018 | $77.74M | +38.6% |
| FY2017 | Dec 31, 2017 | $56.08M | -16.4% |
| FY2016 | Dec 31, 2016 | $67.06M | +73.5% |
| FY2015 | Dec 31, 2015 | $38.65M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.17B | +117.7% |
| Q1 FY2026 | Mar 31, 2026 | $763.95M | +34.1% |
| Q4 FY2025 | Dec 31, 2025 | $777.78M | +27.8% |
| Q3 FY2025 | Sep 30, 2025 | $504.60M | +19.8% |
| Q2 FY2025 | Jun 30, 2025 | $538.83M | +23.6% |
| Q1 FY2025 | Mar 31, 2025 | $569.78M | +16.9% |
| Q4 FY2024 | Dec 31, 2024 | $608.48M | +78.0% |
| Q3 FY2024 | Sep 30, 2024 | $421.09M | +103.2% |
| Q2 FY2024 | Jun 30, 2024 | $436.07M | +79.1% |
| Q1 FY2024 | Mar 31, 2024 | $487.60M | +829.6% |
| Q4 FY2023 | Dec 31, 2023 | $341.86M | +380.5% |
| Q3 FY2023 | Sep 30, 2023 | $207.27M | +126.4% |
| Q2 FY2023 | Jun 30, 2023 | $243.53M | +128.2% |
| Q1 FY2023 | Mar 31, 2023 | $52.45M | -36.9% |
| Q4 FY2022 | Dec 31, 2022 | $71.14M | -35.3% |
| Q3 FY2022 | Sep 30, 2022 | $91.57M | -29.1% |
| Q2 FY2022 | Jun 30, 2022 | $106.71M | -27.4% |
| Q1 FY2022 | Mar 31, 2022 | $83.17M | -49.2% |
| Q4 FY2021 | Dec 31, 2021 | $109.93M | -32.0% |
| Q3 FY2021 | Sep 30, 2021 | $129.06M | -17.1% |
| Q2 FY2021 | Jun 30, 2021 | $146.98M | -15.0% |
| Q1 FY2021 | Mar 31, 2021 | $163.61M | +152.6% |
| Q4 FY2020 | Dec 31, 2020 | $161.62M | +94.3% |
| Q3 FY2020 | Sep 30, 2020 | $155.63M | +55.5% |
| Q2 FY2020 | Jun 30, 2020 | $172.91M | +47.2% |
| Q1 FY2020 | Mar 31, 2020 | $64.78M | -49.6% |
| Q4 FY2019 | Dec 31, 2019 | $83.18M | +7.0% |
| Q3 FY2019 | Sep 30, 2019 | $100.10M | +40.4% |
| Q2 FY2019 | Jun 30, 2019 | $117.49M | +47.4% |
| Q1 FY2019 | Mar 31, 2019 | $128.52M | +158.1% |
| Q4 FY2018 | Dec 31, 2018 | $77.74M | +38.6% |
| Q3 FY2018 | Sep 30, 2018 | $71.28M | +17.8% |
| Q2 FY2018 | Jun 30, 2018 | $79.71M | +18.7% |
| Q1 FY2018 | Mar 31, 2018 | $49.79M | -18.7% |
| Q4 FY2017 | Dec 31, 2017 | $56.08M | -16.4% |
| Q3 FY2017 | Sep 30, 2017 | $60.50M | -16.0% |
| Q2 FY2017 | Jun 30, 2017 | $67.14M | – |
| Q1 FY2017 | Mar 31, 2017 | $61.27M | – |
| Q4 FY2016 | Dec 31, 2016 | $67.06M | – |
| Q3 FY2016 | Sep 30, 2016 | $72.06M | – |
See a number that looks wrong?